Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

830 - Preliminary results of HKNPC-1001 trial to evaluate the role of induction TPF followed by weekly docetaxel and cetuximab in combination with intensity modulated radiotherapy for locally recurrent nasopharyngeal carcinoma


20 Dec 2015


Poster presentation 2


Roger Ngan


Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527


R.K. Ngan1, W.T. Ng2, D.L. Kwong3, S. Tung4, C.C. Yau5, S.F. Leung6, W.Y. Chan2, M. Lung3, A.W. Lee3

Author affiliations

  • 1 Clinical Oncology, Queen Elizabeth Hospital, 1 - Kowloon/HK
  • 2 Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong/HK
  • 3 Clinical Oncology, The University of Hong Kong, Hong Kong/HK
  • 4 Clinical Oncology, Tuen Mun Hospital, Tuen Mun/HK
  • 5 Clinical Oncology, Princess Margaret Hospital, Kowloon/HK
  • 6 Clinical Oncology, Prince of Wales Hospital, Shatin/HK


Abstract 830


This phase II trial aims to study the efficacy of using induction TPF chemotherapy (docetaxel, cisplatin and fluorouracil) for 3 cycles followed by weekly docetaxel and cetuximab in concurrence with Intensity Modulated Radiotherapy (IMRT) re-irradiation in patients with advanced locoregional recurrent nasopharyngeal carcinoma (NPC).


We aim to enroll 45 patients with recurrent NPC (T3 – T4, N0 – N1, M0) to be treated with TPF induction chemotherapy (docetaxel 75 mg/m2 D1, cisplatin 75 mg/m2 D1, fluorouracil 750 mg/m2 D1-D4) every 3 weeks for 3 cycles, followed by weekly docetaxel (15 mg/m2) and cetuximab (400 mg/m2 in initial dose, then 250 mg/m2 in subsequent doses) for 7 weeks in concurrence with IMRT (60Gy over 30 fractions, 5 fractions per week). So far, 32 patients have been recruited: 26 patients had completed the treatment, 1 died and 5 patients withdrew from study after 1 cycle of TPF. The median follow-up period was 19 months.


The local progression free rate at 2 years was 74.2%. The 2 year overall survival was 66.8%. The most frequently reported acute side effects (≥grade 3) in TPF induction phase were neutropenia (37.5%) and hyponatremia (28.1%) and 5 patients withdrew after the first cycle of TPF due mostly to fatigue. During IMRT, the most common acute side effect (≥grade 3) was mucositis (23.0%). So far, 12.5% patients had died of cancer. Temporal lobe necrosis (TLN) developed in 8 cases and 5 patients died due to treatment related complications (2 epistaxis, 1 TLN, 1 sudden death after cycle 1 TPF and 1 chest infection after completion of whole course of treatment).


In this preliminary analysis, induction TPF appears to be poorly tolerated. Promising early local control and survival rates achieved after intensive chemo-re-irradiation should be carefully weighed against the occurrence of potentially lethal early toxicities and late complications.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings